Ultragenyx Pharmaceutical reported $0 in Debt for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Agios Pharmaceuticals AGIO:US USD 1.14M 84K
Alnylam Pharmaceuticals ALNY:US USD 1.02B 338.25M
Aptinyx Inc APTX:US USD 24.71M 211K
Biocryst Pharmaceuticals BCRX:US USD 713.65M 91.47M
Biomarin Pharmaceutical BMRN:US USD 1.08B 986K
Esperion Therapeutics ESPR:US USD 259.49M 407K
Insmed INSM:US USD 807.82M 491K
Karyopharm Therapeutics KPTI:US USD 302.89M 201K
Kyowa Hakko Kirin 4151:JP JPY 24.44B 2.56B
Moderna Inc MRNA:US USD 1.15B 384M
Neurocrine Biosciences NBIX:US USD 169.2M 200K
Ptc Therapeutics PTCT:US USD 1.06B 145.39M
Puma Biotechnology PBYI:US USD 97.99M 312K
Regeneron Pharmaceuticals REGN:US USD 2.7B 400K
Sarepta Therapeutics SRPT:US USD 1.54B 441.9M
Vertex Pharmaceuticals VRTX:US USD 442.3M 40M